Decrease in Lymphoid Specific Helicase and 5-Hydroxymethylcytosine is Associated with Metastasis and Genome Instability.

Jiantao Jia,Ying Shi,Ling Chen,Weiwei Lai,Bin Yan,Yiqun Jiang,Desheng Xiao,Sichuan Xi,Ya Cao,Shuang Liu,Yan Cheng,Yongguang Tao
DOI: https://doi.org/10.7150/thno.21389
IF: 11.6
2017-01-01
Theranostics
Abstract:DNA methylation is an important epigenetic modification as a hallmark in cancer. Conversion of 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) by ten-eleven translocation (TET) family enzymes plays an important biological role in embryonic stem cells, development, aging and disease. Lymphoid specific helicase (LSH), a chromatin remodeling factor, is regarded as a reader of 5-hmC. Recent reports show that the level of 5-hmC is altered in various types of cancers. However, the change in 5-hmC levels in cancer and associated metastasis is not well defined. We report that the level of 5-hmC was decreased in metastatic tissues of nasopharyngeal carcinoma, breast cancer, and colon cancer relative to that in non-metastasis tumor tissues. Furthermore, our data show that TET2, but not TET3, interacted with LSH, whereas LSH increased TET2 expression through silencing miR-26b-5p and miR-29c-5p. Finally, LSH promoted genome stability by silencing satellite expression by affecting 5-hmC levels in pericentromeric satellite repeats, and LSH was resistant to cisplatin-induced DNA damage. Our data indicate that 5-hmC might serve as a metastasis marker for cancer and that the decreased expression of LSH is likely one of the mechanisms of genome instability underlying 5-hmC loss in cancer.
What problem does this paper attempt to address?